Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 5:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: NERVES Clear all
Completed Phase 2 Interventional Results available

Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)

NCT00610129
View directory record Official record
Conditions
Neuroendocrine Tumors, Metastatic Neuroendocrine Tumors
Interventions
MK-0646
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Sep 10, 2026, 5:44 AM EDT
Completed Phase 1 Interventional

Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas

NCT02829931
View directory record Official record
Conditions
Malignant Glioma
Interventions
Hypofractionated Stereotactic Irradiation, Nivolumab, Bevacizumab, Ipilimumab
Radiation · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Tampa, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Sep 10, 2026, 5:44 AM EDT
Completed Not applicable Interventional Results available

Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma

NCT01005745
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Surgery, Administration of Lymphodepletion, Adoptive Cell Transfer, High Dose IL-2
Procedure · Drug · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 10, 2026, 5:44 AM EDT
Withdrawn Not applicable Interventional

Carpal Tunnel Release Effects on Median Nerve Perfusion

NCT01610739
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
Indigocyanine green dye
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Sep 10, 2026, 5:44 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

NCT04201457
View directory record Official record
Conditions
Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1
Interventions
Dabrafenib, Trametinib, Hydroxychloroquine
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
1 Year to 30 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 10, 2026, 5:44 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

NCT05238883
View directory record Official record
Conditions
Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma, Testicular Germ Cell Tumor, Cervical Cancer, Mesothelioma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
HFB200301, Tislelizumab
Drug
Lead sponsor
HiFiBiO Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 10, 2026, 5:44 AM EDT
Completed Phase 3 Interventional

Bevonescein for Intra-Operative Nerve Visualization in Head and Neck Surgery

NCT05377554
View directory record Official record
Conditions
Surgery
Interventions
Bevonescein, Intraoperative Visualization using White Light Reflectance (WLR) with Fluorescence (FL) Overlay, Intra-operative Visualization using White Light Reflectance (WLR)
Drug · Other
Lead sponsor
Alume Biosciences, Inc.
Industry
Eligibility
16 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 10, 2026, 5:44 AM EDT
Terminated Phase 3 Interventional Results available

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

NCT04410445
View directory record Official record
Conditions
Melanoma, Melanoma Stage III, Melanoma Stage IV, Melanoma (Skin)
Interventions
Bempegaldesleukin, Nivolumab
Biological
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
765 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
62
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Anaheim, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Sep 10, 2026, 5:44 AM EDT
Terminated Not applicable Interventional Results available

Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)

NCT01925573
View directory record Official record
Conditions
RECURRENT GLIOBLASTOMA, Brain Tumor
Interventions
Optune(NOVOTTF-100A)
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
22 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Sep 10, 2026, 5:44 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Mirdametinib in People With Central Nervous System Tumors

NCT07539441
View directory record Official record
Conditions
Central Nervous System Tumors, Glioma
Interventions
Mirdametinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 10, 2026, 5:44 AM EDT
Completed Not applicable Interventional

Patient Outcomes With Endoscopic Versus Open Carpal Tunnel Release

NCT00880295
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
endoscopic carpal tunnel release, open carpal tunnel release
Procedure
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Sep 10, 2026, 5:44 AM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma

NCT00589875
View directory record Official record
Conditions
Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High Grade Glioma
Interventions
CAN-2409, Valacyclovir, Temozolomide, Radiation therapy
Biological · Drug · Radiation
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
4
States / cities
Duarte, California • Chicago, Illinois • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Sep 10, 2026, 5:44 AM EDT
Completed Phase 1Phase 2 Interventional Results available

18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

NCT01806675
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Brain Tumor, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Hypopharyngeal Cancer, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Laryngeal Cancer, Recurrent Lip and Oral Cavity Cancer, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Nasopharyngeal Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Oropharyngeal Cancer, Recurrent Pancreatic Cancer, Recurrent Paranasal Sinus and Nasal Cavity Cancer, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer, Recurrent Salivary Gland Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVA Salivary Gland Cancer, Stage IVB Colon Cancer, Stage IVB Salivary Gland Cancer, Stage IVC Salivary Gland Cancer, Tongue Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
Drug
Lead sponsor
Sanjiv Sam Gambhir
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Sep 10, 2026, 5:44 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas

NCT02831257
View directory record Official record
Conditions
Neurofibromatosis 2, Meningioma
Interventions
AZD2014
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 12, 2022 · Synced Sep 10, 2026, 5:44 AM EDT
Terminated Not applicable Interventional

Corneal Neurotization as a Treatment for Neurotrophic Keratopathy

NCT05809245
View directory record Official record
Conditions
Neurotrophic Corneal Ulcer, Neurotrophic Keratitis, Cranial Nerve V Diseases
Interventions
Corneal neurotization
Procedure
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Sep 10, 2026, 5:44 AM EDT
Recruiting Phase 2 Interventional

Effect of Superior Laryngeal Nerve Blocks on Patient Outcomes in Laryngeal Surgery

NCT06734975
View directory record Official record
Conditions
Vocal Cord Disease, Vocal Cord Polyp, Vocal Cord Cyst
Interventions
Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension), Superior laryngeal nerve block - Placebo (saline)
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 10, 2026, 5:44 AM EDT
Completed Not applicable Interventional Results available

Accurate DCE-MRI Measurement of Glioblastoma Using Point-of-care Portable Perfusion Phantom

NCT05140902
View directory record Official record
Conditions
Glioblastoma
Interventions
Point-of-care Portable Perfusion Phantom (P4)
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Sep 10, 2026, 5:44 AM EDT
Terminated Phase 1 Interventional

A Phase 1 Study of [225Ac]-FPI-1434 Injection

NCT03746431
View directory record Official record
Conditions
Advanced Solid Tumours, Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Adrenocortical Carcinoma, Uveal Melanoma
Interventions
[111In]-FPI-1547 Injection, [225Ac]-FPI-1434 Injection multi-dose, FPI-1175 Infusion, [225Ac]-FPI-1434 Injection single-dose
Drug · Biological
Lead sponsor
Fusion Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Duarte, California • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 10, 2026, 5:44 AM EDT
Recruiting Early Phase 1 Interventional

Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy

NCT05921253
View directory record Official record
Conditions
Breast Cancer, Lymphoma
Interventions
PARASYM neuromodulation device
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 10, 2026, 5:44 AM EDT
Completed Phase 2 Interventional Results available

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

NCT02844439
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma, Brain Tumor
Interventions
Tesevatinib
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
11
States / cities
Tucson, Arizona • Duarte, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Sep 10, 2026, 5:44 AM EDT
Recruiting Not applicable Interventional

Self-applied taVNS for CIPN

NCT07596030
View directory record Official record
Conditions
Chemotherapy Induced Peripheral Neuropathy
Interventions
Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 10, 2026, 5:44 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients

NCT04526730
View directory record Official record
Conditions
Melanoma
Interventions
Tavo, Nivolumab, OncoSec Medical Electroporation Therapy System
Drug · Device
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 10, 2026, 5:44 AM EDT
Completed Phase 1 Interventional

A Study of PRT1419 in Patients With Advanced Solid Tumors

NCT04837677
View directory record Official record
Conditions
Sarcoma, Melanoma, Lung Cancer, Breast Cancer, Esophageal Cancer, Cervical Cancer, Head and Neck Cancer
Interventions
PRT1419
Drug
Lead sponsor
Prelude Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Denver, Colorado • Lake Mary, Florida • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Sep 10, 2026, 5:44 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Targeting Language-specific and Executive-control Networks With Transcranial Direct Current Stimulation in Logopenic Variant PPA

NCT03887481
View directory record Official record
Conditions
Logopenic Progressive Aphasia, Primary Progressive Aphasia
Interventions
High-definition active tDCS (HD-tDCS) + "Repeat After Me" (RAM) Treatment, Sham + "Repeat After Me" (RAM) Treatment
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 10, 2026, 5:44 AM EDT